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ABSTRACT
Objective: We have compared  diffusion-weighted magnetic 
resonance  imaging (DW-MRI) properties of mediastinal lymph 
nodes in lung cancer patients with positron emission tomography/
computed tomography (PET/CT) findings. 
Patients and Methods: Twenty-one consecutive untreated 
patients with lung cancer were included. DW-MRI was performed 
on a 1,5T scanner with b values of 50, 500 and 1000. Additional 
MR imaging was performed for anatomical correlation. 
Results: A total of 47 lymph nodes were analyzed. While no 
correlation was found between minimum apparent diffusion 
coefficient  (ADC) values (ADCmin) of lymph nodes and their 
maximum standardized uptake values (SUVmax) on PET/CT, 
ADCmin ratios of lymph nodes to main lesion (ADCmin Node/
Lesion) (r = - 0.407; p = 0.005) and lymph node to cerebrospinal 
fluid (ADCmin Node/CSF) (r = - 0.364; p = 0.012) were correlated 
with SUVmax.  Cutoff values for DW-MRI parameters were 
determined using ROC analysis. Six lymph nodes were 
histopathologically examined. Both methods correctly identified 
one metastatic and two metastasis negative lymph nodes, while 
staging one lymph node with  granulomatous change as metastasis 
positive. Two metastasis negative lymph nodes, reported as 
suspicious on PET/CT, were correctly staged on DW-MRI. 
Conclusion: Our findings indicate that DW-MRI could be at 
least as valuable as PET/CT in mediastinal staging of patients with 
lung cancer.
Key words: Diffusion magnetic resonance imaging, Positron-
emission tomography/Computed tomography, Lung neoplasms, 
Lymph nodes, Mediastinum
ÖZET
Amaç: Akciğer kanserli hastalarda mediastinal lenf nodu 
tutulumunun değerlendirmesinde difüzyon ağırlıklı manyetik 
rezonans görüntüleme (DA-MRG) bulguları ile pozitron emisyon 
tomografisi/bilgisayarlı tomografi (PET/BT) bulguları arasındaki 
ilişkiyi incelemek. 
Hastalar ve Yöntem: Tedavi almamış, ardışık 21 akciğer 
kanserli hasta çalışmaya dahil edildi. DA-MRG 1,5T alan gücüne 
sahip cihaz ile b 50, 500 ve 1000 değerlerinde yapıldı. Anatomik 
korelasyon amaçlı ek incelemeler yapıldı. 
Bulgular: Toplamda 47 lenf nodu değerlendirildi. Lenf 
nodlarının minimum göreceli difüzyon katsayı (ADCmin) 
değerleri ile PET/BT’ de ölçülen maksimum standardize tutulum 
değerleri (SUVmax) arasında anlamlı ilişki saptanmazken, 
ADCmin değerlerinin ana kitle ve beyin omurilik sıvısının 
ADCmin değerlerine oranlandığında elde edilen oranlar ile 
SUVmax değerleri arasında ilişkili bulundu (sırasıyla r = - 0,407; 
p = 0,005 ve r = - 0,364 ve p = 0,012). ROC analizi kullanılarak 
metastaz için eşik değerler belirlendi. Altı lenf nodu histopatolojik 
olarak değerlendirildi. PET/BT ve DA-MRG bir metastaz pozitif 
ve iki metastaz negatif lenf nodunu doğru evrelerken, her ikisi de 
granülomatöz değişiklik barındıran bir lenf nodunda yanlış pozitif 
sonuç verdi. Histopatolojik olarak metastaz negatif olan iki lenf 
nodu PET/BT’de şüpheli sonuç verirken, DA-MRG bu lenf 
nodlarını doğru evreledi. 
Sonuç: DA/MRG, akciğer kanserli hastalarda mediastinal lenf 
nodlarının değerlendirilmesinde en az PET/BT kadar başarılı 
olabilir.
Anahtar kelimeler: Difüzyon manyetik rezonans görüntüleme, 
Pozitron-emisyon tomografi/Bilgisayarlı tomografi, Akciğer 
tümörleri, Lenf nodları, Mediasten
Introduction
Lung cancer is the leading cause of cancer related deaths in 
the world. Treatment is given according to the stage of the 
disease. Early stage lung cancer, having the possibility of 
cure, is treated surgically, while advanced stages are not. 
Lymph node involvement is an important factor affecting 
the stage of the disease [1].
Positron emission tomography (PET), or more commonly, 
positron emission tomography/computed tomography (PET/
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CT) is the method of choice in the assessment of nodal 
involvement. 
PET/CT requires the administration of the radioactive 
substance18 F-2-flouro-2-deoxy-D-glucose (FDG). The 
relative unavailability of PET and PET/CT scanners and 
difficulties in the production, acquisition, and transport of 
FDG are limiting factors for the method.  
Diffusion weighted magnetic resonance imaging 
(DW-MRI) of lymph nodes has been studied in various 
anatomical regions, especially in the head and neck. 
Previous studies have yielded promising results in the 
discrimination between benign and malignant lymph nodes 
[2, 3]. Mediastinal lymph nodes have also been studied with 
DW-MRI [4-7].  Authors have used different and sometimes 
cumbersome methods and parameters in their studies, 
which are not useful for day-to-day practice.
The aim of this study is to search for practical and 
reproducible parameters in the assessment of mediastinal 
lymph nodes in patients with lung cancer using DW-MRI 
and imaging relationship with PET/CT.
Patients and Method
This prospective study was carried out between September 
2009 – June 2010 on 21 consecutive patients with a 
pathologically confirmed diagnosis of lung cancer, who 
were submitted to our Nuclear Medicine Department for 
staging purposes. Patients had not received any treatment 
before imaging. DW-MRI was carried out before or after 
the PET/CT scan, but prior to any treatment, with no more 
than 1 month between both studies. Our study was approved 
by Marmara University, School of Medicine Ethics 
Committee and written informed consent was obtained 
from all patients. 
All MR imaging studies were performed on a 1,5T 
scanner (Magnetom Vision, Siemens, Erlangen, Germany) 
using a surface coil. Patients were scanned from the thoracic 
inlet superiorly to the cardiac apex inferiorly. Diffusion 
weighted images were obtained in three orthogonal planes 
using a non-breathold, single shot echo planar trace method 
with chemical shift selective fat suppression with b values 
of 50, 500, and 1000, TR/TE: 4600/88 ms, FOV: 400 mm, 
Slice Thickness: 5 mm, Interslice Gap: 1mm, NEX: 4. T2 
weighted gradient echo (TRUFI; TR/TE: 3,79/1,56 ms, Flip 
Angle: 60°, FOV: 400mm, Slice Thickness: 5 mm, Interslice 
Gap: 1mm, NEX: 1), T1 weighted spin echo (TR/TE: 
289/4,76 ms, Flip Angle: 70°, FOV: 400mm, Slice 
Thickness: 5 mm, Interslice Gap: 1mm, NEX: 1) and T2 
weighted turbo spin echo images with chemical shift fat 
suppression (TR/TE: 4300/103 ms, Flip Angle: 170°, FOV: 
400mm, Slice Thickness: 5 mm, Interslice Gap: 1mm, 
NEX: 1) were obtained for anatomical correlation. All scans 
were performed in the axial plane. Total imaging time was 
between 5-6 minutes. 
Images were evaluated on a Leonardo workstation 
(Siemens, Erlangen, Germany). ADC maps were 
automatically generated from b50 and b1000 diffusion 
weighted images. A freehand region of interest (ROI) was 
drawn on the the image with the maximum diameter of a 
lymph node. Minimum and average ADC values (ADCmin 
and ADCavg) were recorded. 
PET/CT imaging was performed on a Discovery STE 
(General Electric, Milwaukee, Wisconsin, US) scanner with 
16 channel CT and Bismuth-Germanium oxide (BGO) 
crystal PET equipment. Every patient fasted for at least 6 
hours before the exam. FDG was administered at a dose of 
2,5 MBq/kg of body weight. Patients rested for 
approximately one hour for the metabolic distribution of 
FDG, after which they were scanned from the skull base to 
the midthigh. CT scanning was performed with the 
following parameters: kVp 120, mA/s: 110, slice thickness 
3,8 mm, Pitch: 1,5. PET imaging was performed three 
dimensionally with 3-4 minutes of imaging time per bed 
position and a total imaging time of 15-20 minutes. 
Volumetric regions of interest (VOI) were drawn on each 
lymph node to determine its standardized uptake value 
(SUVmax). An SUVmax of ≥2,5 was considered positive 
for malignancy. Lymph nodes without any FDG uptake 
were given a SUVmax value of 1.
To minimize possible artifacts, ratios between ADCmin 
values of lymph nodes and those of the primary lesion 
(ADCmin Node/Lesion), of CSF (ADCmin Node/CSF), 
and spinal cord (ADCmin Node/SC) were calculated. 
ADCmin values of the primary lesion were measured at 
the level of its maximum diameter. ADCmin values of the 
spinal cord were recorded at the level of the given lymph 
node. ADCmin value of the cerebrospinal fluid was 
measured at the widest space available, irrespective of its 
level. Care was taken not to include any surrounding tissue 
while placing ROIs for measurements. These ratios, as 
well as the ADC values of lymph nodes, were then 
compared to the SUVmax values of lymph nodes for any 
relationship.  
Patients were followed up for any surgical intervention 
in order to obtain histopathological results for any given 
lymph node. 
Statistical analysis (except ROC analysis) was 
performed using SPSS v17 software for Windows. 
Relationships between DW-MRI parameters and SUVmax 
were evaluated using correlation analysis and the Spearman 
correlation coefficient was computed. Any significant 
difference in DW-MRI parameters between the PET/CT 
positive and negative groups were studied using the Student 
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t-test, with p values of <0.05 being considered as significant. 
Threshold values of DW-MRI parameters for PET/CT 
positivity were calculated using the  receiver operating 
characteristic (ROC) analysis with   MedCalc v12 software 
for Windows. 
Results
Eighteen of the twenty-one patients were male and three 
were female with an age range of 40-81 (Mean 63.52 ± 
10.62). A total of 48 lymph nodes were found in 21 patients, 
39 were PET/CT positive (81.2%) and 9 were PET/CT 
negative (18.8%). One PET/CT positive lymph node was 
excluded from final analysis because it was outside of our 
imaging area in DW-MRI.
The final analysis group consisted of 47 lymph nodes. 
Lymph node sizes were between 4.5 – 23 mm (mean 11 mm 
±4.9 mm). Minimum ADC values of lymph nodes ranged 
between 0.14 -1.59x10-3 mm2/s  (mean 0.6 ± 0.26 x10-3 
mm2/s) and  SUVmax values ranged between 1-24.3 (mean 
6.23 ±5.05). Mean time between the PET/CT and MRI 
scans was 5.51 (±6.5) days (Range 0-28 days). 
The most significant relationship was found between 
SUVmax and ADCmin Node/Lesion (Spearman’ s Rho r = 
- 0.407 and p = 0.005). There was also a significant 
relationship between ADCmin Node/CSF (r = - 0.364 and 
p=0.012). There was no significant relationship between 
ADCmin (r = - 0.235 and p = 0.112), ADCavg (r = - 0.122 
and p = 0.416), and ADCmin  Node/SC values (r = - 0.248 
and p = 0.092) and SUVmax of lymph nodes.  
DW-MRI parameters significantly different between 
PET/CT positive and negative groups were: ADCmin Node/
SC (PET (+) M=0.6 SD=0.34; PET (-) M=0.954 SD=0.337; 
p=0.015), ADCmin Node/Lesion (PET (+) M=1.167 
SD=0.469; PET (-) M=2.743 SD=1.598; p=0.018), ADCmin 
(PET (+) M=44.973 SD=16.074; PET (-) M=81.111 
SD=42.348; p=0.034), and ADCmin Node/CSF (PET (+) 
M=0.32 SD=0.16; PET (-) M=0.786 SD=0.549; p=0.035). 
DW-MRI parameters were significantly lower in the PET/
CT positive group.
After the ROC analysis, the Youden Index method 
revealed a threshold value of ≤1.57 for ADCmin Node/
Lesion ratio (AUC = 0.846; CI(95) = 0.712-0,935; 
p<0,001). It had 84% sensitivity, 78% specificity for PET/
CT positivity. Values ≤2.149 had 95% sensitivity, while 
values ≤1.057 had 95% specificity for PET/CT positivity.
Five patients underwent surgery and six lymph nodes 
were histopathologically evaluated. One lymph node 
harbored a metastatic focus (Figure 1), five were metastasis 
negative. PET/CT was positive for the metastatic lymph 
node and the ADCmin Node/Lesion ratio was 1.21. 
Of the five metastasis negative lymph nodes, one 
contained granulomatous change which was PET/CT 
positive (false positive), and the ADCmin Node/Lesion 
ratio was also found to be 1.21 (Figure 2). Two lymph 
nodes with SUVmax values of 2.1 and 2.6 were reported as 
“suspicious” on PET/CT. Their ADCmin Node/Lesion 
ratios were 2.25 and 5.58 respectively. The remaining two 
lymph nodes were PET/CT negative and their ADCmin 
Node/Lesion ratios were 1.62 and 3.38. 
Discussion
Computed tomography (CT) is the most widely used 
method for the evaluation of lymph nodes, because of its 
wide availability and repeatability. It is not, however, 
valuable in the detection of lung cancer metastases with 
sensitivities of 52-64% and specificities of 62-69% [8, 9]. 
The superiority of FDG-PET over CT in the evaluation 
of mediastinal lymph nodes has been proven in meta-
analytic studies [10, 11]. In a prospective study with 102 
patients, the sensitivity and specificity of FDG-PET in the 
detection of mediastinal lymph node metastases was found 
to be 91% and 86% respectively [12]. The main advantages 
of FDG-PET are its ability to detect metastatic lypmh nodes 
smaller than 1 cm in size and its high negative predicitive 
value [13, 14]. 
In PET/CT, metabolic data of FDG-PET are fused with 
anatomic images of CT. This method was found to be 
superior to FDG-PET alone [15]. Antoch et al. compared 
PET/CT to FDG-PET in their study on non small cell lung 
cancer patients and found that PET/CT changed tumor stage 
in 26% and the choice of treatment in 15% of their patients 
[16]. 
The main disadvantage of FDG-PET, and thus PET/CT, 
is its high rate of false positivity [17, 18]. The main factors 
causing false positivity in FDG-PET are inflammatory and 
granulomatous diseases [11, 14, 19, 20]. Al-Sarraf et al. 
have found that, even when not in its active stage, exposure 
to tuberculosis led to an 8 fold increase in false positivity 
[20]. On the other hand, the low spatial resolution of the 
camera (low sensitivity for objects under 7 mm) and diabetes 
may lead to false negativity [11, 20]. Additionally, PET/CT 
is still not as widely available as CT or MRI. Patients 
receive injections of FDG, a radioactive material, and have 
to rest for approximately one hour after the injection.
With the development of fast imaging methods like echo 
planar imaging (EPI), DW-MRI has also been used on body 
imaging. Characterization of lymph nodes with DW-MRI 
has been studied especially in the cervical and pelvic 
regions, with promising results in the discrimination 
between benign vs. malignant lymph nodes [21-24]. 
DW-MRI of mediastinal lymph nodes however, is a less 
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studied area probably due to respiratory and cardiac motion 
artifacts, which interfere with ADC measurements [25]. 
We used DW-MRI parameters as suggested by previous 
authors [25, 26]. To increase patient cooperation, a non-
breathold method without cardiac gating was used. ADC 
figures were calculated using b 50 and b 1000 values. 
DW-MRI at b 50 values is less prone to signal changes 
related to capillary perfusion than imaging at b 0 [25]. 
There are no standardized criteria for the evaluation of 
lymph nodes on DW-MRI. When evaluating diffusion 
weighted images, hyperintense lymph nodes should not be 
assumed to be malignant because lymph nodes have varying 
signal properties even at high b values [7, 25]. Some 
investigators have used multiple ROI measurements with 
minimum pixels and averaged the results (ADCavg) on 
ADC maps, while others have placed the ROI on 
hyperintense areas of the b1000 diffusion images and 
copied this ROI onto the ADC map [25, 27]. deBondt et al. 
suggest that if ADCavg values are to be used,  necrotic 
areas of lymph nodes on conventional images should be 
excluded [22]. 
We based our measurements on  minimum ADC values, 
since using average ADC values would require multiple 
measurements to exclude necrotic areas and would conflict 
with our goal: to search for parameters that are easy to use. 
It was also our opinion that using multiple ROIs could 
decrease our sensitivity for detecting small metastatic foci. 
Since none of  the  lymph nodes we studied showed necrotic 
changes, we chose to include ADCavg results (using only 
one ROI) into our analysis. When using ADCmin values 
however, special care must be taken not to include the 
surrounding tisse while placing ROIs. 
There are some inherent pitfalls to be kept in mind in 
the evaluation of lymph nodes with DW-MRI [25]. Lymph 
nodes less than 2-4 mm in size may be too small for 
evaluation. Reactive changes and lymphomas may lead to a 
decrease in ADC values. Partial volume effects, blood 
products (after biopsy), image noise, and motion artifacts 
may interfere with measurements. Micrometastases may not 
cause detectable diffusion restriction. 
Another issue is reproducibility of measurements. Kwee 
et al. studied intra and interobserver reproducibility of ADC 
measurements of lymph nodes in healthy volunteers and 
reported that measurements were only moderately 
repeatable [27]. They noted that differences between ADC 
measurements often exceeded previously reported threshold 
values for benign vs malignant lymph nodes. In the same 
study, Kwee et al. noted that studies for the same pathology 
and lymph node region resulted in different ADC threshold 
values and pointed at the aforementioned differences in 
measurement, hardware, software, and patient artifacts. 
Threshold ADC values of mediastinal lymph nodes also 
differ between studies. Usuda et al. based their 
measurements on average ADC values and reported a 
threshold value of ADCavg as 1.7x10-3mm2/s [4]. Koşucu 
et al., on the other hand, also used average ADC values and 
reported 1.012±0.025x10-3mm2/s as the threshold value 
with a range between 0.720-1.125x10-3mm2/s [7]. Nomori 
et al., using imaging parameters similar to those of our 
study, reported an ADCmin threshold value of 1.6x10-
Figure 1. Histopathologically confirmed metastasis positive lymph node 
(Arrows). Main lesion and the metastatic lymph node appear bright on 
DW-MRI. The inverted DW-MRI image is shown because of its similarity 
to PET. (a) PET, (b) PET/CT, (c) inverted DW-MRI and (d) ADC map 
images. 
Figure 2. Metastasis negative lymph node containing granulomatous 
change (Arrows). It was incorrectly staged as positive on PET/CT. It also 
had a low ADCmin Node/Lesion ratio, indicating false positive staging on 
DW-MRI, too. (a) PET, (b) PET/CT, (c) inverted DW-MRI and (d) T2 
weighted gradient echo images.
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3mm2/s [5], while the highest ADCmin value in our study 
was 1.59x10-3mm2/s. 
One way to minimize these differences may be to use 
relative ADC values by comparing them to other tissues 
[25, 28]. The place to start is the primary lesion, which is 
the source of the metastasis. While there was no significant 
relationship between ADC values of lymph nodes and 
SUVmax in our study, a highly significant relationship was 
found between the ADCmin Node/Lesion ratio and 
SUVmax. This indicates that patient related imaging 
artifacts greatly influence DWI measurements. 
Uto et al. [29] found that the ratio of the signal intensity 
for the  lesion relative to the spinal cord on high b-value 
DWI was useful in differentiating between malignant and 
benign lung nodules. In our study, however, there was no 
significant relationship between ADCmin Node/SC and 
SUV max. This might be due to variations of ADC values 
of the spinal cord at different levels and in different age 
groups [30].
We could not find any study exploring the normal range 
of ADC values of CSF in normal subjects or its variation 
with age and sex. The fact that we found a significant 
relationship between the ADCmin Node/CSF ratio and 
SUVmax indicates that it does not differ significantly 
between individuals and can potentially be used as a 
reference for signal intensity in diffusion weighted imaging. 
Except for ADCmin Node/Lesion and Node/CSF, the 
significant differences in DW-MRI parameters between PET/
CT positive and negative groups might be attributed to our 
small sample size, especially in the PET/CT negative group.  
ROC analysis revealed a threshold ADCmin Node/
Lesion value of 1.57 for PET/CT positivity. The metastasis 
positive lymph node (Figure 1), as well as the lymph node 
with granulomatous change (Figure 2), which was PET/CT 
positive, had a ratio of 1.21. Nomori et al [5] reported that 
granulomatous change caused false positive findings in 
DW-MRI in their study. Two metastasis negative lymph 
nodes, reported as suspicous on PET/CT, had ADCmin 
Node/Lesion ratios of 2.25 and 5.58.  
The limiting factors of our study were small sample size 
and the low number of lymph nodes with a pathologically 
confirmed diagnosis. Thus, we could not establish the true 
value of our parameters. Previous studies have reported 
DW-MRI to be a useful method with accuracies superior to 
PET/CT [4-7]. The relationship we found between ADCmin 
Node/Lesion, ADCmin Node/CSF and SUVmax indicates 
similar accuracy values to PET/CT. 
Because of the limitations mentioned above, our study 
should be regarded as preliminary work. Our measurements 
were practical enough to be used in a clinical setting and 
our findings were promising, warranting further studies 
with larger sample sizes to verify our findings.  
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